Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by RA Capital Management L.P.

RA Capital Management L.P. trimmed its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,710,428 shares of the biotechnology company's stock after selling 397,972 shares during the quarter. Ascendis Pharma A/S accounts for approximately 16.7% of RA Capital Management L.P.'s investment portfolio, making the stock its biggest position. RA Capital Management L.P. owned 16.01% of Ascendis Pharma A/S worth $1,449,864,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ASND. DNB Asset Management AS acquired a new position in Ascendis Pharma A/S during the 2nd quarter worth $456,000. SG Americas Securities LLC raised its holdings in Ascendis Pharma A/S by 221.0% in the second quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company's stock valued at $833,000 after acquiring an additional 4,205 shares in the last quarter. Legato Capital Management LLC lifted its stake in Ascendis Pharma A/S by 167.6% in the second quarter. Legato Capital Management LLC now owns 4,324 shares of the biotechnology company's stock worth $590,000 after acquiring an additional 2,708 shares during the last quarter. Searle & CO. acquired a new position in Ascendis Pharma A/S during the 2nd quarter worth approximately $205,000. Finally, Rhumbline Advisers grew its holdings in Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock worth $209,000 after acquiring an additional 143 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ASND shares. Wedbush reissued an "outperform" rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Stifel Nicolaus upped their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a "buy" rating in a report on Friday, November 15th. Oppenheimer cut their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a report on Friday, November 15th. Evercore ISI upped their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an "outperform" rating in a report on Tuesday, September 17th. Finally, Wells Fargo & Company boosted their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a research report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Ascendis Pharma A/S has an average rating of "Moderate Buy" and an average target price of $191.77.

Ascendis Pharma A/S Trading Down 0.4 %

Shares of Ascendis Pharma A/S stock traded down $0.54 on Thursday, reaching $130.47. 93,492 shares of the stock were exchanged, compared to its average volume of 450,265. The firm has a market capitalization of $7.91 billion, a PE ratio of -16.21 and a beta of 0.67. Ascendis Pharma A/S has a 1-year low of $101.43 and a 1-year high of $161.00. The business has a fifty day moving average price of $131.07 and a two-hundred day moving average price of $132.51.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. Research analysts expect that Ascendis Pharma A/S will post -7.45 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.